This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
a therapeutic oncology company and 3B Pharmaceuticals (3BP) GmbH, a biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for cancer detection and treatment, announced an exclusive licensing agreement for RefleXion to develop and commercialize a specific 3BP molecule to direct its SCINTIX biology-guided radiotherapy.
Beyder, along with Vikas Prasad, MD, PhD, and BJH/WU Radiation Oncology all played an integral role in launching the SNMMI radiopharmaceutical therapy (RPT) comprehensive center of excellence at WU, Barnes-Jewish Hospital, and Siteman Cancer Center last year. Involve radiation safety early in your therapy center development.
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclear medicine, diagnostic radiology, and radiation oncology. led by Harshad Kulkarni, MD, as principal investigator.
The Evanston, IL-based company specializes in delivering dosimetry analysis and treatment plans to clinical research organizations and pharmaceutical manufacturers. Dosimetry-as-a-service provider TeleDaaS made its official debut at RSNA 2023.
The ASRT weighed in, telling AuntMinnie.com, "A key issue we continue to face is state legislation designed to weaken or remove licensure for medical imaging and radiation therapy professionals. For CT and MRI procedures where injected contrast media is ordered, ".
Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.
TerraPower Isotopes has shipped its first samples of Actinium-225 (Ac-225) to two pharmaceutical companies to develop targeted cancer treatments in drug trials. Ac-225 is an alpha-emitting radionuclide that can be attached to a ligand that binds to cancer cells.
Ac-225 to Curadh for use in its pioneering molecularly targeted radiation (MTR) programs for the treatment of common lethal tumors. “We Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. actinium-225 (Ac-225).
Clarity Pharmaceuticals has completed its third cohort in the theranostic SECuRE trial evaluating copper-64 (Cu-64) and copper-67 (Cu-67) sarcophagine chelator technology in patients with metastatic castration-resistant prostate cancer.
The company is a pre-clinical stage biotech company focused on advancing the field of radiation oncology through accelerator-based Boron Neutron Capture Therapy (BNCT), based in Santa Monica, CA. Hill joined TAE Life Sciences as Chief Operating Officer (COO) in October 2018.
CNL will provide the starting material for irradiation and initially manage the production process during the interim scale of radiochemical grade 225Ac supply, while ITM will further process the resulting 225Ac to pharmaceutical grade under Good Manufacturing Process (GMP) specifications.
Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Ac-225 carries sufficient radiation to cause cell death in a localized area of targeted cells, while its half-life limits unwanted radioactivity in patients. NorthStar is positioned to be the first commercial-scale producer of n.c.a.
Recognizing the industry transformation taking place as digital innovation reshapes the experience of patients and providers, GE HealthCare – a leading global medical technology, pharmaceutical diagnostics, and digital innovator – is focused on developing smart devices, aligned to disease states and enabled by digital.
announced the acquisition’s close and addition of MIM Software’s imaging analytics and digital workflow solutions as a part of its leading global medical technology, pharmaceutical diagnostics, and digital portfolio. There is also special focus on radiation therapy and Theranostics. Oncotarget. 2017 Jun 8;8(37):62742-62758.
This unit will enable us to develop and manufacture patient doses for pharmaceutical or biotechnology companies as well as share our radiopharmaceutical development and commercialization expertise with them where they may require additional infrastructure, resources or the specialized knowledge required for complex radiopharmaceutical development.
TeleDaaS specializes in delivering clinical-grade, precision-based dosimetry analysis and treatment plans to clinical research organizations (CROs) and pharmaceutical manufacturers.
Imaging AI models can inform contrast or radiation dosimetry, identify crucial information about patients such as age or underlying conditions for emergency response triaging, run scan quality assessments to automate transformations, flag equipment or patient positioning concerns, and identify lesions in a scan for an expert eye to confirm.
For postreaction patients, various therapies are being tested, including oral steroids, synthetic vitamin D3 to slow skin growth, white blood cell radiation treatment to soften plaque, and plasmapheresis for blood purification. It would be unreasonable to rule out other factors that could play a role in NSF.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
105 
Let's personalize your content